Skip to content

Comparing the Effect of Oral Misoprostol and Intravenous Oxytocin on Labor Induction

Comparing the Effect of Oral Misoprostol and Intravenous Oxytocin on Labor Induction in pregnant women

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171111037374N1
Enrollment
140
Registered
2018-07-03
Start date
2017-12-22
Completion date
Unknown
Last updated
2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Abdominal pregnancy. Condition 2: (Induced) termination of pregnancy with other and unspecified complications. Abdominal pregnancy (Induced) termination of pregnancy with other and unspecified complications

Interventions

Intervention 1: Intervention group: 50 micrograms of oral misoprostol for induction of labor. If no appropriate uterine contractions were observed, patients received 50 mg Misoprostol every four hour

Sponsors

Fasa University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Gestational age more than 42 weeks first and second pregnancy women over 18 years old singleton pregnancy, cervical closure (Bishop score greater than six)

Exclusion criteria

Exclusion criteria: Multiple pregnancies need for immediate cesarean section history of uterine scarring placenta previa vaginal bleeding more than normal postpartum bleeding heart, liver and kidney diseases history of sensitivity to Oxytocin, Misoprostol or prostaglandin analogues severe congenital anomalies in the fetus.

Design outcomes

Primary

MeasureTime frame
Delivery withing 48 hours after intervention. Timepoint: 48 hours after intervention. Method of measurement: Recording the number of patients with successful delivery within 48 hours.;Route of delivery. Timepoint: At time if delivery. Method of measurement: Recording the route of delivery (Cesarean or vaginal delivery).;Neonatal Apgar. Timepoint: 1 and 5 minutes after birth. Method of measurement: Apgar.

Secondary

MeasureTime frame
Adverse Effects. Timepoint: 1, 2, 4, 8 and 10 days after intervention. Method of measurement: Adverse drug effects form.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Kokabi

Fasa University of Medical Sciences

roya.kokabi11111@gmail.com+98 71 5335 0994

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026